Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Terminated 1Suspended 1

Sponsor Class

OTHER 2NETWORK 2NIH 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 6Sarcoma 1

Conditions

Glioblastoma 4Medulloblastoma 2Recurrence 1Neoplasms 1Gliosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 41Temozolomide 34Specimen Handling 32Radiotherapy 20Radiation 15Biopsy 13Radiosurgery 12Nivolumab 11X-Rays 9Cyclophosphamide 9Ipilimumab 7Bevacizumab 7Nuclear Medicine Department, Hospital 6Lomustine 6Cisplatin 6Carboplatin 6Phantoms, Imaging 5Irinotecan 5CTLA-4 Antigen 5AZD 6244 5trametinib 4erdafitinib 4Vincristine 4Topotecan 4Surveys and Questionnaires 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Mental Status and Dementia Tests 4Etoposide 4ulixertinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Lomustine × CNS × 30 days × Clear all
NCT06325683 2026-05-26

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Suspended
184 enrolled
CNS

Glioblastoma

NCT02724579 2026-05-20

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Children's Oncology Group

Phase 2 Active not recruiting
45 enrolled
CNS

Medulloblastoma

NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

NCT05382338 2026-05-05

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Children's Oncology Group

Phase 3 Recruiting
225 enrolled
CNS

Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡